7). These results may provide novel RG7204 chemical structure prognostic and predictive factors for early-recurrent HCC disease and the design of novel miRNA-based therapeutic strategies against HCC. Immunohistochemical staining was performed by the Advanced Molecular Pathology Laboratory,
The Institute of Molecular and Cell Biology, Singapore’s Agency for Science, Technology and Research. Additional Supporting Information may be found in the online version of this article. Table S1. Primers for qRT-PCR analysis Table S2. Predicted targets of miR-216a/217 Figure S1. Schematic diagram illustrating the overall strategy of this study. The study was initiated by the identification of miRNAs associated with early recurrent HCC disease by comparing the miRNA expressions between early-recurrent and non-recurrent human HCC tissue samples by miRNA microarrays (Fig. 1A). Among the various differentially expressed miRNAs identified between early-recurrent and non-recurrent HCC samples, the expression of miR-216a/217
was chosen to be further examined in learn more detail and validated by real-time quantitative RT-PCR (Fig 1B and 1C). It was also observed that elevated miR-216a/217 expression was significantly associated with poor disease-free survival by Kaplan-Meier survival analysis (Fig. 1D and 1E). To dissect the molecular roles of miR-216a/217 in early-recurrent HCC disease, we studied the expression of miR-216a/217 in a panel of liver cancer cell lines (Fig. 2A and 2B). It was demonstrated that the up-regulation of miR-216a/217 was associated with cell EMT phenotype (Fig. 2C and 2D) and the migratory ability of these cells (Fig. 2E). Establishing that the over-expression of miR-216/217 was associated with cell EMT phenotype and migratory ability of HCC cell lines enabled us to further study the biological activity of miR-216a/217 in vitro and in vivo. We additionally demonstrated that the stable overexpression of miR-216a/217 increased the stem-like cell population (Fig 3A-3D)
and enhanced the metastatic ability of HCC cells with epithelial cell morphology (Fig. 3E and 3F). Subsequent bioinformatics analysis, luciferase report assay and western blotting studies identified PTEN and SMAD7 as two functional targets selleck kinase inhibitor of miR-216a/217 (Fig. 4A and 4B). This observation was corroborated with the down-regulation of both PTEN and SMAD7 in samples from HCC patients with early recurrent disease (Fig. 4C and 4D) and was significantly associated with disease-free survival of HCC patients (Fig. 4E and 4F). Furthermore, ectopic expression of PTEN or SMAD7 could partially rescue miR-216a/217-mediated EMT (Fig. 5A and 5B), cell migratory ability (Fig. 5C) and stem-like properties of HCC cells with epithelial cell morphology (Fig. 5D and 5E).